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Background: Since the burden of neuropathic pain (NeP) increases with pain severity, it is 
important to characterize and quantify pain severity when identifying NeP patients. This study 
evaluated whether painDETECT, a screening questionnaire to identify patients with NeP, can 
distinguish pain severity.
Materials and methods: Subjects (n=614, 55.4% male, 71.8% white, mean age 55.5 years) 
with confirmed NeP were identified during office visits to US community-based physicians. 
The Brief Pain Inventory – Short Form stratified subjects by mild (score 0–3, n=110), moder-
ate (score 4–6, n=297), and severe (score 7–10, n=207) average pain. Scores on the nine-item 
painDETECT (seven pain-symptom items, one pain-course item, one pain-irradiation item) 
range from -1 to 38 (worst NeP); the seven-item painDETECT scores (only pain symptoms) 
range from 0 to 35. The ability of painDETECT to discriminate average pain-severity levels, 
based on the average pain item from the Brief Pain Inventory – Short Form (0–10 scale), was 
evaluated using analysis of variance or covariance models to obtain unadjusted and adjusted (age, 
sex, race, ethnicity, time since NeP diagnosis, number of comorbidities) mean painDETECT 
scores. Cumulative distribution functions on painDETECT scores by average pain severity 
were compared (Kolmogorov–Smirnov test). Cronbach’s alpha assessed internal consistency 
reliability.
Results: Unadjusted mean scores were 15.2 for mild, 19.8 for moderate, and 24.0 for severe 
pain for the nine items, and 14.3, 18.6, and 22.7, respectively, for the seven items. Adjusted nine-
item mean scores for mild, moderate, and severe pain were 17.3, 21.3, and 25.3, respectively; 
adjusted seven-item mean scores were 16.4, 20.1, and 24.0, respectively. All pair-wise com-
parisons of scores between pain-severity groups showed sizable and statistically significant 
differences (P,0.0001). Cumulative distribution functions showed distinct separation between 
severity (P,0.0001). Cronbach’s alphas were 0.76 and 0.80 for the nine- and seven-item scales, 
respectively.
Conclusion: This study provides strong psychometric evidence on the validity and reliability 
of painDETECT for distinguishing average pain severity in patients with NeP.
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Introduction
Neuropathic pain (NeP), a common cause of chronic pain, results from a variety of 
diseases and medical conditions, and is defined as pain caused by a lesion or disease 
of the peripheral somatosensory nervous system.1 Although heterogeneity in epide-
miologic studies has been a limitation in estimating its presence in the population, best 
estimates suggest that the overall prevalence of pain with neuropathic characteristics is 
between 7% and 10%.2 However, when NeP is present, it is associated with a substantial ClinicoEconomics and Outcomes Research 2014:6 submit your manuscript | www.dovepress.com
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socioeconomic burden that has been characterized not only 
for conditions that are well recognized (eg, painful diabetic 
peripheral neuropathy and chronic low-back pain) but also for 
several that are less frequent (eg, small-fiber neuropathy).3–7 
Furthermore, evidence suggests that the patient and economic 
burdens are higher at greater pain-severity levels.3–7
Because there is only weak evidence for interventional 
management of NeP,8 treatment relies on a pharmacologic 
approach, and guidelines for pharmacologic management of 
NeP have been published.9,10 Despite these recommendations 
and the availability of medications from several drug classes, 
NeP management remains challenging, not least because of 
the need for appropriate identification of NeP when making 
treatment decisions.
To identify the presence of NeP in patients reporting 
chronic pain, differences in the symptoms and descriptions of 
NeP relative to nociceptive pain were investigated to develop 
various instruments to screen for the likelihood that pain is 
of neuropathic rather than nociceptive origin.11 While some 
instruments, such as the DN4 (Douleur Neuropathique 4)12 and 
the original Leeds Assessment of Neuropathic Symptoms and 
Signs (LANSS)13 include a requirement for clinical examina-
tion, other instruments, such as a patient self-report version of 
the LANSS (S-LANSS),14 as well as painDETECT,15 do not 
require clinical examination. In particular, painDETECT is a 
simple, fully patient-reported questionnaire that has been vali-
dated for screening and identification of components of NeP.15 
In contrast to S-LANSS, which evaluates sensory symptoms 
based on a dichotomous response (yes/no), painDETECT 
consists of 6-point Likert-type scales, which provide a broader 
range or continuum of assessment. Since pain severity is not 
only of immediate importance to patients but also increases 
the overall burden, characterizing pain-severity levels when 
identifying patients with NeP can help inform treatment 
decisions. Although an association between pain severity 
and painDETECT scores was suggested in several studies, 
including the original painDETECT-validation study,15–17 
this relationship has not been psychometrically evaluated 
with the goal of differentiating NeP severity. Therefore, the 
purpose of this study was to determine whether painDETECT 
can differentiate among levels of average pain severity in 
patients with NeP.
Materials and methods
Data source
Data for this analysis were obtained during a cross-sectional, 
observational study on the burden of NeP across six 
NeP conditions: painful diabetic peripheral neuropathy,4 
human immunodeficiency virus-related peripheral NeP,18 
posttrauma/postsurgical NeP,5 spinal cord injury-related 
NeP,6 chronic low-back pain-associated NeP,19 and small-
fiber neuropathy.7 The study was approved by a central 
institutional review board (Concordia Clinical Research, 
Cedar Knolls, NJ, USA), and collection and analysis of data 
were compliant with the Health Insurance Portability and 
Accountability Act.
subjects
Subjects with a confirmed diagnosis of any of the six con-
ditions were identified during routine office visits at 33 
community-based physician practices across the US between 
September 2011 and June 2012. Study sites included gen-
eral practitioners (n=9), neurologists (n=7), pain specialists 
(n=6), endocrinologists (n=3), and other specialists (eg, 
orthopedist, infectious disease specialist, podiatrist, rheu-
matologist; n=8).
For inclusion, subjects were required to be adults 
($18 years old) diagnosed with their NeP at least 6 months 
prior to enrollment, managed by the physician’s practice for at 
least 6 months, and had experienced NeP symptoms for at least 
the prior 3 months. Exclusion criteria were participation in an 
investigational drug study in the past 6 months; presence of a 
serious or unstable medical or psychological condition that in 
the opinion of the physician would compromise participation 
in the study; or having a concomitant illness unrelated to NeP 
that could have confounded the assessment of NeP.
Outcomes
Subjects were asked to complete a series of self-administered, 
one-time questionnaires during the office visit that included 
patient-reported measures of pain, function, quality of life, 
and productivity, as previously described.4,6,7 Of relevance to 
the current analysis, the questionnaire included the Brief Pain 
Inventory – Short Form (BPI-SF)20 and the painDETECT 
questionnaire.15
Patients were stratified based on their level of average pain 
within the past 24 hours using the average pain item from the 
BPI-SF, which consists of an 11-point numeric rating scale 
(0= no pain to 10= pain as bad as you can imagine). Pain-
severity levels based on previously established cut points 
were defined as mild (score 0–3), moderate (score 4–6), and 
severe (score 7–10).21
painDETECT is a nine-item questionnaire that consists of 
seven sensory symptom items for pain that are graded from 
0= never to 5= strongly, one temporal item on pain-course 
pattern graded -1 to +1, and one spatial item on pain   radiation ClinicoEconomics and Outcomes Research 2014:6 submit your manuscript | www.dovepress.com
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graded 0 for no radiation or +2 for radiating pain. A total 
score that ranges from -1 to 38 can be calculated from the 
nine items, with higher scores indicating higher levels of NeP. 
Although the nine-item questionnaire demonstrated strong 
predictive ability for NeP, principal-component analysis 
identified the seven sensory items as driving the data structure 
of the questionnaire.15 Therefore, the seven-item version of 
painDETECT that only includes the sensory symptom items 
and a total score that ranges from 0 to 35 was also evaluated 
for its ability to differentiate pain severity.
statistical analyses
Scores on painDETECT were derived for subjects who 
had no missing responses on the sensory items (seven- and 
nine-item scales), and response was also required on the pain-
course item on the nine-item scale. Scale-level discrimination 
was evaluated using unadjusted and adjusted models.22 The 
ability of painDETECT to discriminate between average 
pain-severity levels of mild, moderate, and severe, based on 
the average pain item from the BPI-SF as described earlier, 
was determined using analysis of variance or covariance 
models (both models used Tukey’s adjustment for pair-wise 
comparisons) to obtain, respectively, unadjusted and adjusted 
mean painDETECT scores. Factors in the adjusted models 
were age, sex, race, ethnicity, time since NeP diagnosis, and 
number of comorbidities.
The corresponding mean scores on painDETECT 
between pairs of severity groups were translated into 
standardized effect sizes,22 derived by taking the differ-
ence between pair-wise means and dividing them by the 
pooled standard deviation on painDETECT across the 
three severity groups. By convention, a standardized effect 
size of 0.20 is considered “small”, while 0.50 and 0.80 are 
“medium” and “large”, respectively.23   Additionally, cumu-
lative   distribution of painDETECT scores by   (average) pain 
severity were plotted and compared using the Kolmogorov–
Smirnov test.24
Scale-level reliability was evaluated using Cronbach’s 
alpha (covariance-based formula)22 to determine the internal 
consistency reliability of the nine- and seven-item versions 
of painDETECT. Assessment of item-level discrimination 
was performed using corrected item-to-total correlations22 to 
determine how well each item discriminated across neuro-
pathic levels of pain as measured by painDETECT.22 These 
were “corrected” to account for item overlap by deleting the 
item under consideration from the total score. All analyses 
and statistics were performed using SAS version 9.2 (SAS 
Institute, Cary, NC, USA).
Results
subject characteristics
The study enrolled 624 subjects who were identified with 
the NeP conditions, with approximately the same number 
of subjects from each NeP condition. Data on average pain 
severity were available for 614 subjects, with an average 
pain-severity distribution of 17.9%, 48.4%, and 33.7% for 
mild, moderate, and severe pain, respectively (Table 1). 
These subjects were 55.4% male and predominantly white 
(71.8%), with a mean (standard deviation) age of 55.5 (13.7) 
years (Table 1). However, with increasing levels of pain 
severity, significant trends were observed across severity 
levels (P,0.05) toward younger age, higher proportion of 
females, longer duration since NeP diagnosis, and more 
comorbid conditions (Table 1).
Among the 614 subjects with pain-severity data, the 
response rate for the painDETECT questionnaire was 96.9% 
and 98.7% for the nine- and seven-item versions, respectively; 
only two subjects (one mild and one moderate pain) had nine-
item scores despite a missing pain-radiation item (which was 
taken to indicate no radiating pain and hence given a value 
of 0). Similar proportions of subjects across the pain-severity 
categories completed both versions (Table 1).
scale-level discrimination
On the nine-item version of painDETECT, unadjusted mean 
scores were 15.2, 19.8, and 24.0, for mild, moderate, and 
severe pain, respectively (Figure 1A). These scores differenti-
ated between levels of average reported pain, with all pair-
wise comparisons statistically significant (P,0.0001). The 
significant differentiation between all pair-wise comparisons 
was maintained for the adjusted mean scores of 17.3 (mild), 
21.3 (moderate), and 25.3 (severe) (P,0.0001) (Figure 1B). 
Similarly, for the seven-item version, both the unadjusted 
(Figure 1C) and adjusted painDETECT (Figure 1D) scores 
differentiated between average pain-severity levels, as 
indicated by the statistical significance for all pair-wise 
comparisons (P,0.0001).
Standardized effect sizes were slightly lower (with no 
practical importance) for adjusted mean scores relative to 
unadjusted mean scores, and if anything slightly lower for 
the seven-item version than the nine-item version (Table 2). 
Both the nine-item scores and the seven-item scores showed 
separation with respect to the three levels of average pain 
severity, with strength of differentiation that was at least 
medium (effect sizes $0.50) across all comparisons, even 
after adjustment (Table 2). While the magnitude of separa-
tion was in the medium range for mild versus moderate pain ClinicoEconomics and Outcomes Research 2014:6 submit your manuscript | www.dovepress.com
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Table 1 Demographic and clinical characteristics by neuropathic pain severity
Characteristic Milda (n=110) Moderatea (n=297) Severea (n=207) P-valueb
age, years, mean (sD) 58.3 (15.1) 55.7 (13.2) 53.6 (13.3) 0.0293
sex, n (%) 0.0222
  Male 71 (64.5) 169 (56.9) 101 (48.8)
  Female 39 (35.5) 128 (43.1) 106 (51.2)
Race, n (%) 0.0015
  american indian or alaska native 1 (0.9) 3 (1.0) 5 (2.4)
  asian 1 (0.9) 2 (0.7) 2 (1.0)
  Black or african american 13 (11.8) 37 (12.5) 47 (22.7)
  White 89 (80.9) 230 (77.4) 122 (58.9)
  Multiracial 2 (1.8) 4 (1.3) 5 (2.4)
  Other 3 (2.7) 15 (5.1) 22 (10.6)
  Missing 1 (0.9) 6 (2.0) 4 (1.9)
Ethnicity, n (%) 0.0151
  non-hispanic 100 (90.9) 266 (89.6) 168 (81.2)
  hispanic 5 (4.5) 21 (7.1) 27 (13.0)
  Missing 5 (4.5) 10 (3.4) 12 (5.8)
BPi-sF pain-severity index, mean (sD) 2.0 (1.1) 5.2 (0.8) 7.7 (1.1) na
Time since neP diagnosis, years, mean (sD) 6.3 (5.9) 7.9 (6.8) 8.5 (7.2) 0.0059
number of comorbid conditions, mean (sD) 2.0 (1.8) 2.5 (2.2) 3.3 (2.4) ,0.0001
neuropathic pain condition, n (%) na
  Painful diabetic peripheral neuropathy (n=111) 22 (20.0) 57 (19.2) 32 (15.5)
    Human immunodeficiency virus-related  
peripheral neP (n=102)
24 (21.8) 41 (13.8) 37 (17.9)
  Posttrauma/postsurgical neP (n=97) 14 (12.7) 48 (16.2) 35 (16.9)
  spinal cord injury-related neP (n=101) 21 (19.1) 53 (17.8) 27 (13.0)
  neP in chronic low-back pain (n=104) 6 (5.5) 55 (18.5) 43 (20.8)
  Small-fiber neuropathy (n=99) 23 (20.9) 43 (14.5) 33 (15.9)
painDETECT completion, n (%) na
  nine-item version 106 (96.4) 291 (98.0) 198 (95.7)
  seven-item version 108 (98.2) 292 (98.3) 206 (99.5)
Notes: aAverage pain severity was classified based on the Brief Pain Inventory – Short Form scores of 0–3 for mild, 4–6 for moderate, and 7–10 for severe pain; bP-values 
across pain-severity levels are from the Kruskal–Wallis test for continuous variables; from the χ2 test for number of comorbid conditions, and from Fisher’s exact test for 
the remaining categorical variables.
Abbreviations: na, not applicable; sD, standard deviation; BPi-sF, Brief Pain inventory – short Form; neP, neuropathic Pain.
and moderate versus severe pain, it was consistently large 
for mild versus severe pain.
The cumulative frequency-distribution plots for 
painDETECT scores are shown in Figure 2 for the nine-item 
version (Figure 2A) and the seven-item version (Figure 2B). 
Both versions demonstrated differentiation between pain-
severity levels that was statistically significant for all 
pair-wise comparisons (P,0.0001); for each painDETECT 
score, the proportion of patients at that score or lower (more 
favorable score) was greater at lower levels of pain severity. 
For example, for the seven-item score, approximately 20% 
of subjects in the severe group had scores of 18 or lower 
(better), compared with approximately 45% and 70% in the 
moderate and mild pain groups, respectively.
scale-level reliability
Across all subjects and pain-severity categories, corrected 
item-to-total correlations showed discernible and sizable 
amounts of item discrimination for all items on the seven-
item version, which ranged from 0.49 for “slight pressure 
triggers pain” to 0.62 for “light touching painful” (Table 3). 
The same set of items on the nine-item version was equally 
discriminating, as indicated by similar values for the cor-
rected item-to-total correlation (Table 3). However, the 
two additional items showed low or no discrimination (pain 
radiation, 0.21; pain course, -0.08). Despite having two 
fewer items, the seven-item version gave a slightly higher 
Cronbach’s alpha (0.80) than the nine-item version (0.76).
Discussion
This study compellingly demonstrated the psychometric 
validity and reliability of painDETECT for distinguishing 
mild, moderate, and severe levels of average pain in subjects 
with NeP, with pain severity rated using the average pain 
item from the BPI-SF. Specifically developed screening 
instruments, such as painDETECT, have been shown to be ClinicoEconomics and Outcomes Research 2014:6 submit your manuscript | www.dovepress.com
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Figure 1 (A–D) Mean painDETECT scores across pain-severity categories for average pain. (A) nine-item unadjusted scores; (B) nine-item adjusted scores; (C) seven-item 
unadjusted scores; (D) seven-item adjusted scores.
Table 2 standardized effect sizes for pair-wise comparisons of 
painDETECT scores
Comparison  
between  
average pain- 
severity levels
Standardized effect sizea
Nine-item version Seven-item version
Unadjusted Adjusted Unadjusted Adjusted
Mild versus  
moderate
-0.65 -0.56 -0.63 -0.55
Mild versus  
severe
-1.25 -1.13 -1.23 -1.12
Moderate  
versus severe
-0.60 -0.57 -0.60 -0.57
Note: anegative values represent less neuropathic pain in the group with the lower 
level of average pain severity.
useful in identifying the likelihood that pain is of neuro-
pathic origin.11 Although there is a need for characterizing 
and quantifying NeP concurrently with its identification in 
patients with various NeP conditions, to our knowledge, no 
other NeP instrument has yet been specifically validated for 
distinguishing between levels of average pain severity. These 
results therefore complement and extend studies that have 
suggested that NeP-screening instruments may help distin-
guish among sensory symptom profiles and pain-severity 
levels.16,17,25–27
Both the seven-item and nine-item scores of painDETECT 
provided good discrimination (known-group validity) 
of average pain severity, with significant differentiation 
(P,0.0001) for all pair-wise comparisons between mild, 
moderate, and severe pain. The extent of the separation was 
substantial based on estimation of standardized effect sizes: 
medium magnitude for mild versus moderate pain and for 
moderate versus severe pain, and large magnitude for mild 
versus severe pain. Although it can be expected that a similar 
set of results would apply to the similarly phrased BPI-SF 
questions on worst pain, least pain, and current pain, further 
research would be needed for their confirmation.
These findings, while new and clinically relevant, are 
not entirely unexpected, given the previously observed 
relationship between painDETECT and pain severity. The 
initial painDETECT-validation study reported a significant 
association (P,0.001) between pain severity (average over ClinicoEconomics and Outcomes Research 2014:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
502
Cappelleri et al
Two previous studies have also suggested that pain-
symptom descriptors may be significant predictors of NeP 
severity.28,29 In those studies, the presence of a higher number 
of descriptors, as well as specific descriptor qualities, had 
greater predictive value for more severe pain.28,29 The range 
of descriptors constituting painDETECT overlaps with 
those descriptors that have shown predictive ability for pain 
severity. Taken in context, the current results confirm and 
supplement the relevance of using descriptors for character-
izing NeP, including for quantifying severity, and provide 
reassuring evidence that the observed results enhance the 
clinical usefulness of painDETECT in ways not previously 
validated.
Both the seven-item version and the nine-item version 
demonstrated internal consistency reliability that was accept-
able (above 0.70). However, the seven-item version resulted 
in a slightly higher reliability (Cronbach’s α=0.80) than the 
nine-item version (Cronbach’s α=0.76) and more consistent 
item-level discrimination. The reliability of the seven-item 
version is not only similar to that reported in the validation 
study (Cronbach’s α=0.83),15 but its higher value than the 
nine-item version is also in concordance with previous 
observations,27 suggesting that the two nonsensory items 
are not psychometrically compatible with the sensory items. 
While further confirmation for the greater reliability of the 
seven-item version is needed, it can nevertheless be recom-
mended that the seven sensory items be used together; the two 
nonsensory items, on temporal and spatial characterization 
of the pain pattern, that are included in the nine-item version 
can be analyzed and interpreted separately.
It should also be noted that since the population in the 
current study consisted of patients with confirmed NeP, the 
cumulative distribution curves are in marked contrast to 
those in studies evaluating discrimination between main pain 
subtypes (nociceptive, pure neuropathic, mixed) where the 
nociceptive group clearly resulted in lower (more   favorable) 
scores on painDETECT.15,27 In addition, in the current study, 
the cumulative distributions convincingly showed that pain-
DETECT scores were dependent on the degree of average 
pain severity for patients with confirmed NeP; fitting only 
one curve for all patients with NeP (ie, without regard to 
average pain severity), as has been done previously,15,27 
would mask this finding.
At least two possible limitations of this research should 
be noted. One is that the study was cross-sectional rather 
than longitudinal. The opportunity to link changes in pain-
DETECT scores to changes in average pain severity was not 
available. However, painDETECT has generally been used 
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Figure 2 Cumulative frequency distribution by average pain severity for (A) nine-
item painDETECT scores and (B) seven-item painDETECT scores.
Table 3 Corrected item-to-total correlations for the nine- and 
seven-item painDETECT
painDETECT item Nine-item  
version
Seven-item 
version
Burning sensation 0.48 0.51
Tingle or prickling sensation 0.59 0.61
light touching painful 0.60 0.62
sudden pain attacks like electric shocks 0.49 0.50
Cold or heat painful 0.55 0.54
sensation of numbness 0.45 0.48
slight pressure triggers pain 0.49 0.49
Pain radiation 0.21 –
Pain course -0.08 –
the past 4 weeks) and painDETECT scores,15 and other stud-
ies have confirmed that higher painDETECT scores were 
significantly associated with greater average pain severity 
over the previous 4 weeks (P,0.05).16,17 However, those 
studies evaluated the relationship within the framework 
of the painDETECT cutoff values for differentiating NeP 
from nociceptive pain. In contrast, the current study started 
with a large and varied NeP population, and quantified both 
unadjusted and adjusted mean painDETECT values based 
on pain-severity levels.ClinicoEconomics and Outcomes Research 2014:6 submit your manuscript | www.dovepress.com
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as a screening tool at a single time point, since its respon-
siveness to change over time or with treatment has not been 
adequately evaluated.
The second limitation is that this study could be poten-
tially criticized for evaluation of a population that included 
different NeP conditions, since it can be argued that there 
may be differences among the conditions resulting from their 
various etiologies. However, it has been reported that there 
appear to be greater similarities than differences overall with 
regard to NeP regardless of etiology.25,26
Furthermore, a recent study suggested that there may 
be up to four distinct pain-characteristic profiles that are 
independent of etiology.26 Therefore, since the scoring of 
painDETECT is based on an amalgam of frequency and 
severity for relevant individual sensory symptoms, severity 
discrimination will likely be maintained even across the dif-
ferent sensory symptom profiles, supporting a robust ability 
of painDETECT to both identify NeP and profile its sensi-
tivity with respect to average pain regardless of the etiology 
or sensory profile. It could be argued that the wide range of 
average pain severity and NeP across etiologies is intended to 
foster a diverse and expansive base of patients that resounds 
in drawing stronger psychometric results and inferences to 
patients with NeP regardless of etiology.
Conclusion
This study provides strong psychometric evidence on the 
validity of painDETECT for distinguishing scores on NeP 
based on scores of average pain severity for patients with 
NeP. Therefore, the ability of painDETECT to discriminate 
among mild, moderate, and severe levels of average pain 
further supports the measurement properties and clinical 
relevance of this instrument for identifying and characterizing 
NeP. The nine-item and seven-item versions of painDETECT 
also show satisfactory reliability, but the higher reliability of 
the seven-item version suggests it may be more prudent to 
use this version, with the two nonsensory items used sepa-
rately to further characterize NeP. Additional investigation 
of the psychometric properties of painDETECT and other 
NeP-screening instruments are warranted, since more com-
prehensive characterization of NeP at screening can inform 
management strategies that may help improve outcomes and 
reduce the disease burden.
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